Interleukin-21 (IL-21) activity in patients (pts) with metastatic melanoma (MM)

被引：5
|
作者：
Petrella, T. M.
Tozer, R.
Belanger, K.
Savage, K. J.
Wong, R.
Kamel-Reid, S.
Tron, V.
Chen, B.
Hunder, N. N.
Eisenhauer, E. A.
机构：
[1] Odette Canc Ctr, Toronto, ON, Canada
[2] Juravinski Canc Ctr, Hamilton, ON, Canada
[3] Hop Notre Dame de Bon Secours, Montreal, PQ H2L 4K8, Canada
[4] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[5] CancerCare Manitoba, Winnipeg, MB, Canada
[6] Univ Hlth Network, Toronto, ON, Canada
[7] Queens Univ, Kingston, ON, Canada
[8] NCIC Clin Trials Grp, Kingston, ON, Canada
[9] Zymogenetics Inc, Seattle, WA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.8507
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8507
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Preliminary tolerability and anti-tumor activity of intravenous recombinant human Interleukin-21 (IL-21) in patients with metastatic melanoma and metastatic renal cell carcinoma.
    Curti, BD
    Redman, BG
    Thompson, JA
    Sievers, EL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 166S - 166S
  • [2] Identification of a well-tolerated outpatient regimen of interleukin-21 (IL-21) in patients with metastatic melanoma and renal cell carcinoma (RCC)
    Thompson, JA
    Curti, BD
    Redman, BG
    Sievers, EL
    JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) : 641 - 642
  • [3] Recombinant human Interleukin-21 (IL-21) is well tolerated and can mediate biological effects in patients with metastatic melanoma (MM): preliminary results of a phase 1 study
    Davis, Ian D.
    McArthur, Grant
    Cebon, Jonathan
    Frederiksen, Klaus S.
    Lundsgaard, Dorthe
    Skak, Kresten
    Skrumsager, Birte K.
    CANCER RESEARCH, 2006, 66 (08)
  • [4] Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study
    Petrella, Teresa M.
    Tozer, Richard
    Belanger, Karl
    Savage, Kerry J.
    Wong, Ralph
    Smylie, Michael
    Kamel-Reid, Suzanne
    Tron, Victor
    Chen, Bingshu E.
    Hunder, Naomi N.
    Hagerman, Linda
    Walsh, Wendy
    Eisenhauer, Elizabeth A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27) : 3396 - 3401
  • [5] Caspase-8 cleavage of the interleukin-21 (IL-21) receptor is a negative feedback regulator of IL-21 signaling
    Akagi, Tatsuya
    Shimizu, Kouhei
    Takahama, Shoukichi
    Iwasaki, Takahiro
    Sakamaki, Kazuhiro
    Endo, Yaeta
    Sawasaki, Tatsuya
    FEBS LETTERS, 2011, 585 (12) : 1835 - 1840
  • [6] Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease
    Monteleone, Giovanni
    Pallone, Francesco
    Macdonald, Thomas T.
    CYTOKINE & GROWTH FACTOR REVIEWS, 2009, 20 (02) : 185 - 191
  • [7] Interleukin-21 (IL-21): Tolerability and anti-tumor activity following two 5-day cycles in patients with stage IV melanoma (MM) or renal cell carcinoma (RCC).
    Thompson, J. A.
    Curti, B. D.
    Redman, B. G.
    Weber, J. S.
    Agarwala, S. S.
    Sievers, E. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 101S - 101S
  • [8] Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses
    Parrish-Novak, J
    Foster, DC
    Holly, RD
    Clegg, CH
    JOURNAL OF LEUKOCYTE BIOLOGY, 2002, 72 (05) : 856 - 863
  • [9] Semisynthetic Study of Interleukin-21(IL-21) using Novel Peptide Preparation Method
    Izawa, Nana
    Maki, Yuta
    Okamoto, Ryo
    Kajihara, Yasuhiro
    GLYCOBIOLOGY, 2023, 33 (11) : 1081 - 1081
  • [10] Altered circulating and local expression of interleukin-21 and IL-21 receptor in granulomatosis with polyangiitis
    Weppner, G.
    Holl-Ulrich, K.
    Hasselbacher, K.
    Riemekasten, G.
    Lamprecht, P.
    Mueller, A.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2017, 47 : 128 - 128
12345